Ironwood Pharmaceuticals, Inc. (IRWD) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$4.17
Price Target
$4.80
Target Range
$3.70 — $5.70
Analyst Rating
Hold
Forward P/E3.1x
Trailing P/E27.8x
Forward PEG—
Implied Growth+882.0%
Median Target$5.00
Analyst Spread41.7%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$4
-11.3%
Consensus
$5
+15.1%
Bull Case
$6
+36.7%
IRWD Price Target Analysis
Updated May 8, 2026As of May 8, 2026, Ironwood Pharmaceuticals, Inc. (IRWD) has a Wall Street consensus price target of $4.80, based on estimates from 30 covering analysts. With the stock currently trading at $4.17, this represents a potential upside of +15.1%. The company has a market capitalization of $680M.
Analyst price targets range from a low of $3.70 to a high of $5.70, representing a 42% spread in expectations. The median target of $5.00 aligns closely with the consensus average.
The current analyst consensus rating is Hold, with 11 analysts rating the stock as a Buy or Strong Buy,16 rating it Hold, and 3 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, IRWD trades at a trailing P/E of 27.8x and forward P/E of 3.1x. Analysts expect EPS to grow +882.0% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+51.9%
Avg Forward P/E15.4x
Peers with Coverage8 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 PTGXProtagonist Therapeutics, Inc. | $6.4B | $98.85 | $116.75 | +18.1% | Buy | 30.6x | 26 |
 ARDXArdelyx, Inc. | $1.7B | $6.98 | $17.00 | +143.6% | Buy | — | 16 |
 CPIXCumberland Pharmaceuticals Inc. | $65M | $4.33 | — | — | — | — | — |
 SUPNSupernus Pharmaceuticals, Inc. | $3.0B | $52.28 | $60.00 | +14.8% | Buy | 24.1x | 14 |
 PRGOPerrigo Company plc | $1.6B | $11.72 | $20.00 | +70.6% | Hold | 5.6x | 36 |
 SHPHShuttle Pharmaceuticals Holdings, Inc. | $4M | $0.71 | — | — | — | — | — |
 VNDAVanda Pharmaceuticals Inc. | $378M | $6.39 | $14.17 | +121.8% | Buy | — | 19 |
 JAZZJazz Pharmaceuticals plc | $14.2B | $226.96 | $216.14 | -4.8% | Buy | 9.4x | 48 |
 PCRXPacira BioSciences, Inc. | $930M | $23.64 | $29.50 | +24.8% | Hold | 8.6x | 36 |
 ABBVAbbVie Inc. | $358.4B | $202.64 | $256.64 | +26.6% | Buy | 14.3x | 41 |
Upside Potential Comparison
ARDXVNDAPRGOABBVPCRXPTGXSUPNJAZZSee IRWD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IRWD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IRWD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonIRWD — Frequently Asked Questions
Quick answers to the most common questions about buying IRWD stock.
What is the IRWD stock price target for 2026?
Ironwood Pharmaceuticals, Inc. (IRWD) has a consensus 12-month price target of $4.8, implying 15.1% upside from $4.17. The 30 analysts covering IRWD see moderate appreciation potential.
Is IRWD a buy, sell, or hold?
IRWD has a consensus rating of "Hold" based on 30 Wall Street analysts. The rating breakdown is mixed, with 16 Hold ratings making up the largest segment. The consensus 12-month price target of $4.8 implies 15.1% upside from current levels.
Is IRWD stock overvalued or undervalued?
With a forward P/E of 3.1431x, IRWD trades at a relatively low valuation. The consensus target of $4.8 implies 15.1% appreciation, suggesting meaningful undervaluation.
How high can IRWD stock go?
The most bullish Wall Street analyst has a price target of $5.7 for IRWD, while the most conservative target is $3.7. The consensus of $4.8 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover IRWD stock?
IRWD is heavily covered by Wall Street, with 30 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 11 have Buy ratings, 16 recommend Hold, and 3 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the IRWD stock forecast?
The 12-month IRWD stock forecast based on 30 Wall Street analysts shows a consensus price target of $4.8, with estimates ranging from $3.7 (bear case) to $5.7 (bull case). The median consensus rating is "Hold".
What is IRWD's forward P/E ratio?
IRWD trades at a forward P/E ratio of 3.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 27.8x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy IRWD stock?
Wall Street analysts are optimistic on IRWD, with a "Hold" consensus rating and $4.8 price target (15.1% upside). 11 of 30 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do IRWD price targets vary so much?
IRWD analyst price targets range from $3.7 to $5.7, a 42% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $4.8 consensus represents the middle ground.